for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alexion Pharmaceuticals, Inc.

ALXN.OQ

Latest Trade

98.41USD

Change

-1.58(-1.58%)

Volume

747,628

Today's Range

97.62

 - 

100.40

52 Week Range

92.57

 - 

141.81

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Alexion Receives FDA Approval For Ultomiris For Atypical Hemolytic Uremic Syndrome

Oct 18 (Reuters) - Alexion Pharmaceuticals Inc <ALXN.O>::ALEXION RECEIVES FDA APPROVAL FOR ULTOMIRIS® (RAVULIZUMAB-CWVZ) FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS).ALEXION PHARMACEUTICALS- REGULATORY FILINGS FOR MARKETING AUTHORIZATIONS OF ULTOMIRIS FOR TREATMENT OF AHUS IN EU, JAPAN UNDER REVIEW WITH REGULATORS.

Alexion Pharmaceuticals Says If Merger With Achillion Terminated Under Certain Circumstances, Achillion May Be Required To Pay Co Fee Equal To $20 Million

Oct 16 (Reuters) - Alexion Pharmaceuticals Inc <ALXN.O>::ALEXION PHARMACEUTICALS - IF MERGER WITH ACHILLION TERMINATED UNDER CERTAIN CIRCUMSTANCES, ACHILLION MAY BE REQUIRED TO PAY CO FEE EQUAL TO $20 MILLION.ALEXION - TO PAY ACHILLION TERMINATION FEE EQUAL TO $30 MILLION, $40 MILLION, $50 MILLION OR $60 MILLION DEPENDING ON EXTENSION OF MERGER END DATE, TERMINATION DATE.

Alexion To Acquire Achillion

Oct 16 (Reuters) - Achillion Pharmaceuticals Inc <ACHN.O>::ALEXION TO ACQUIRE ACHILLION.ACHILLION PHARMACEUTICALS INC - INITIAL ALL-CASH TRANSACTION FOR $6.30 PER SHARE.ACHILLION PHARMACEUTICALS INC - DEAL FOR $6.30 PER SHARE.ACHILLION PHARMACEUTICALS INC - TOTAL TRANSACTION OF UP TO $8.30 PER SHARE WITH POTENTIAL ADDITIONAL CONTINGENT CONSIDERATIONS.ACHILLION PHARMACEUTICALS INC - INITIAL DEAL CONSIDERATION OF APPROXIMATELY $930 MILLION.ACHILLION PHARMACEUTICALS INC - ALEXION WILL ALSO BE ACQUIRING CASH CURRENTLY ON ACHILLION'S BALANCE SHEET.ACHILLION PHARMACEUTICALS - DEAL INCLUDES POTENTIAL FOR ADDITIONAL CONSIDERATION IN FORM OF NON-TRADEABLE CONTINGENT VALUE RIGHTS.ACHILLION PHARMA - AS OF SEPT. 30, 2019, CASH CURRENTLY ON ACHILLION'S BALANCE SHEET WAS ABOUT $230 MILLION.ACHILLION PHARMA - CVRS WILL BE PAID TO ACHILLION SHAREHOLDERS IF SOME CLINICAL & REGULATORY MILESTONES ARE ACHIEVED WITHIN SPECIFIED PERIODS.

Alexion And Bridgebio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis Investigational Medicine

Sept 9 (Reuters) - Alexion Pharmaceuticals Inc <ALXN.O>::ALEXION AND BRIDGEBIO ANNOUNCE JAPANESE LICENSE AGREEMENT FOR EIDOS’ TRANSTHYRETIN AMYLOIDOSIS (ATTR) INVESTIGATIONAL MEDICINE.ALEXION PHARMACEUTICALS INC - EIDOS GRANTS ALEXION EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE AG10 IN JAPAN.ALEXION PHARMACEUTICALS - EIDOS TO RECEIVE UPFRONT PAYMENT OF $25 MILLION AND EQUITY INVESTMENT OF $25 MILLION.ALEXION PHARMACEUTICALS INC - PHASE 3 STUDY OF AG10 IN ATTR CARDIOMYOPATHY UNDERWAY IN U.S. & EUROPE.ALEXION PHARMACEUTICALS INC - PHASE 3 TRIAL IN ATTR POLYNEUROPATHY PLANNED TO INITIATE IN SECOND HALF OF 2019.

Alexion Pharmaceuticals Says European Patent Office To Not Grant Co Patent Application Relating To Pharmaceutical Composition Of Soliris

Sept 5 (Reuters) - Alexion Pharmaceuticals Inc <ALXN.O>::ALEXION PHARMACEUTICALS - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF SOLIRIS (ECULIZUMAB).ALEXION PHARMACEUTICALS INC - WILL EVALUATE OPTION TO APPEAL THE EUROPEAN PATENT OFFICE’S DECISION.ALEXION PHARMA - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF MATTER OF SOLIRIS (ECULIZUMAB).

Alexion Pharmaceuticals Q2 Non-GAAP Earnings Per Share $2.64

Alexion Pharmaceuticals Inc <ALXN.O>::ALEXION REPORTS SECOND QUARTER 2019 RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $2.64.Q2 GAAP EARNINGS PER SHARE $2.04.Q2 REVENUE $1.203 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.17 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $2.34 -- REFINITIV IBES DATA.ALEXION PLANS TO FILE FOR REGULATORY APPROVALS IN EU AND JAPAN IN SECOND HALF OF 2019.PLANS TO INITIATE A PHASE 3 STUDY OF ULTOMIRIS IN NMOSD BY END OF 2019, PENDING REGULATORY FEEDBACK.INCREASING FY TOTAL REVENUES AND EPS GUIDANCE.ALEXION PHARMACEUTICALS - DOSING IS UNDERWAY IN A SINGLE, PK-BASED PHASE 3 STUDY OF ULTOMIRIS, DATA ARE EXPECTED IN EARLY 2020.SEES FY TOTAL REVENUES $4,750 MILLION TO $4,800 MILLION.PLANS TO INITIATE A PHASE 3 STUDY OF ULTOMIRIS IN HSCT-TMA IN FIRST HALF OF 2020, PENDING REGULATORY FEEDBACK.SEES FY EARNINGS PER SHARE $8.13 TO $8.41.SEES FY ADJUSTED EARNINGS PER SHARE $9.65 TO $9.85.FY2019 EARNINGS PER SHARE VIEW $9.44, REVENUE VIEW $4.78 BILLION -- REFINITIV IBES DATA.

Alexion Pharmaceuticals Receives Marketing Authorization From EC For Ultomiris For Adults With PNH

July 3 (Reuters) - Alexion Pharmaceuticals Inc <ALXN.O>::ULTOMIRIS® (RAVULIZUMAB) RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).ALEXION PHARMACEUTICALS - EC APPROVAL BASED ON RESULTS FROM TWO PHASE 3 STUDIES.

FDA Grants Approval Of Soliris, A Treatment For Neuromyelitis Optica Spectrum Disorder, To Alexion Pharmaceuticals

June 27 (Reuters) - FDA::FDA APPROVES FIRST TREATMENT FOR NEUROMYELITIS OPTICA SPECTRUM DISORDER, A RARE AUTOIMMUNE DISEASE OF THE CENTRAL NERVOUS SYSTEM.FDA SAYS GRANTED APPROVAL OF SOLIRIS TO ALEXION PHARMACEUTICALS.FDA SAYS SOLIRIS HAS A BOXED WARNING THAT LIFE-THREATENING AND FATAL MENINGOCOCCAL INFECTIONS HAVE OCCURRED IN PATIENTS TREATED WITH SOLIRIS.

Alexion Says FDA Accepted sBLA For Ultomiris Under Priority Review

June 20 (Reuters) - Alexion Pharmaceuticals Inc <ALXN.O>::U.S. FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR ULTOMIRIS® (RAVULIZUMAB-CWVZ) UNDER PRIORITY REVIEW FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS).ALEXION PHARMACEUTICALS INC - FDA SETS TARGET ACTION DATE OF OCTOBER 19, 2019.

Alexion Pharma Reports Positive Extension Data From Late-Stage Study of Ultomiris In Patients With Paroxysmal Nocturnal Hemoglobinuria

June 14 (Reuters) - Alexion Pharmaceuticals Inc <ALXN.O>::POSITIVE PHASE 3 EXTENSION DATA FOR ULTOMIRIS® (RAVULIZUMAB) IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PRESENTED AT EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS.ALEXION PHARMACEUTICALS INC - ULTOMIRIS DEMONSTRATED CONSISTENT EFFICACY AND SAFETY THROUGH 52 WEEKS.ALEXION PHARMACEUTICALS - SUSTAINED EFFICACY OF ULTOMIRIS WAS OBSERVED ON CO-PRIMARY ENDPOINTS OF TRANSFUSION AVOIDANCE & NORMALIZATION OF LDH LEVELS.ALEXION PHARMACEUTICALS - MOST COMMON ADVERSE EVENTS OCCURRED LESS FREQUENTLY IN EXTENSION PHASE THAN DURING INITIAL TREATMENT PHASE FOR ULTOMIRIS.ALEXION PHARMACEUTICALS - SUSTAINED EFFICACY OF ULTOMIRIS WAS OBSERVED ON SECONDARY ENDPOINTS OF LDH LEVEL REDUCTION AND BREAKTHROUGH HEMOLYSIS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up